ARIAD to Present Preclinical Data at AACR Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule ofpreclinical data presentations to be made at the American Association forCancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6through Wednesday, April 10, 2013, in Washington.Listed below are the details of presentations at AACR that describe ARIAD'sproduct candidates. There will be four presentations of data on ARIAD'stargeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk:Title: Ponatinib is a highly potent inhibitor of activated variants of RETfound in MTC and NSCLCDate & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)Abstract: #2084Location: Hall A-C, Poster Section 38Title: Ponatinib potently inhibits the activity of mutant variants of FGFRcommonly found in endometrial, lung and other cancersDate & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)Abstract: #2083Location: Hall A-C, Poster Section 38Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activatingand drug-resistant KIT mutants found in GISTDate & Time: Tuesday, April 9, 8:00 a.m.–12:00 p.m. (Poster)Abstract: #3394Location: Hall A-C, Poster Section 42Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CMLDate & Time: Tuesday, April 9, 9:30–10:00 a.m. (Major symposium)Presentation: #SY19-04Location: Salon A-B, East HallTitle: AP26113 possesses pan-inhibitory activity versus crizotinib-resistantALK mutants and oncogenic ROS1 fusionsDate & Time: Wednesday, April 10, 8:00 a.m.–12:00 p.m. (Poster)Abstract: #5655Location: Hall A-C, Poster Section 42